Treprostinil

Primary pulmonary hypertension (PPH) is a condition of unknown cause that is characterized by increasing pulmonary arterial and vascular resistance. Treprostinil is a stable analog of prostacyclin (Cay-18220) that is used clinically for the treatment of PPH under the trade name Remodulin(TM). The structural modifications in treprostinil compared to prostacyclin increase the plasma half-life from 2 minutes to 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine (TNFalpha, IL-1beta, IL-6, GM-CF) production by human alveolar macrophages in the sub-micromolar range by preventing NF-kappaB translocation to the nucleus.Formal Name: 2-[[(1R,2R,3aS,9aS)-2,3,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]-acetic acid. CAS Number: 81846-19-7. Synonyms: BW 15AU, LRX 15, Rumodolin, U-62840, Uniprost. Molecular Formula: C23H34O5. Formula Weight: 390.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30mg/ml, DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml, DMSO: 20mg/ml, Ethanol: 20mg/ml. lambdamax: 206, 218, 277 nm. SMILES: O=C(O)COC1=C(C[C@](C[C@@H](O)[C@@H]2CC[C@@H](O)CCCCC)([H])[C@]2([H])C3)C3=CC=C1. InChi Code: InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1. InChi Key: PAJMKGZZBBTTOY-ZFORQUDYSA-N.